Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients' longer life expectancy. It has also made breast cancer a chronic disease, increasing the risk of late side effects of oncological therapy. More cardiovascular diseases are diagnose in patients over 65 with an oncological history than in those without it and therefore much effort must be made to maximise effectiveness of the therapy with as few side effects as possible. The article presents two breast cancer patients treated with big doses of liposomal doxorubicin with a good response and almost no side effects.
INTRODUCTION
Breast cancer is the most frequent women's tumor in the world.
In 2012, there were 1,676,000 new breast cancer cases reported worldwide and 17,000 in Poland [1] .
Owing to mammographic screening and women's growing awareness, cancer is more and more often diagnosed at early stages.
Surgery constitutes the basic form of early breast cancer treatment. Adjuvant therapy (chemotherapy, radiotherapy, endocrine therapy, targeted therapy) aims at decreasing the risk of cancer recurrence and prolongation of overall survival [3] .
Sensitive and specific diagnostic methods as well as more and more effective therapies have resulted in breast cancer's becoming a chronic disease; the number of survivors living for years after they have been diagnosed with cancer is constantly growing. However, overall survival is connected with an increased risk of late complications of oncological treatment. Postmenopausal breast cancer patients are more often diagnosed with circulatory system diseases than their age peers never treated oncologically [2] .
Drugs with cardiotoxic potential used in breast cancer treatment include anthracyclines, i.e. cytostatics administered both in early and in advanced breast cancer stages, and trastuzumab -a monoclonal human antibody inhibiting HER2 receptor via blocking HER2 receptor dimerisation with another receptor from the epidermal growth factor receptor family (EGFR). Due to their high therapeutic efficacy, it has not been possible to replace them with any other specifics of a less toxic profile.
Anthracyclines can cause type I (irreversible) cardiotoxicity dependent on the cumulative dose and resulting in permanent changes in cardiomyocyte structure [4] . Trastuzumab, on the other hand, blocking HER2 receptor on the neoplastic cell membrane as well as on the cardiomyocyte membrane, disturbs their function, which is manifested by a lower left ventricular ejection fraction (LVEF). Left ventricular systolic dysfunction, caused by trastuzumab, is most often reversible and asymptomatic, does not depend on the cumulative dose but rather on the patient's general health status, her habits, concomitant diseases and oncological treatment initiated earlier [5] . With follow-up duration time, there is an increased risk of late cardiological complications that can manifest themselves more than one year after discontinuation of the oncological treatment.
Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin J. Kufel-Grabowska Since targeted therapy was excluded, the patient was given liposomal doxorubicin at a dose of 60 mg/m² iv. every 21 days.
Prior to that, echocardiography was carried out: LVEF of 65%, there was no systolic or diastolic dysfunction of the left ventricle. Before the 3 rd chemotherapy course, a follow-up chest X-ray was done: the liquid volume in the left pleural cavity was reduced. The patient experienced general health improvement.
Exertion tolerance increased and cough was only sporadic. The CA 15-3 marker value fell to 140 U/ml. Owing to good tolerance and treatment efficacy, liposomal doxorubicin administration was continued. After another 2 courses (after the 4 th course) a chest CT scan was performed which confirmed general image improvement observed on the X-ray examination; the marker fell to 107 U/ml and the patient reported no disturbing complaints.
After the 6 th chemotherapy course, echocardiography was car- Breast cancer in pregnancy is a malignancy diagnosed during pregnancy or within 12 months after its termination. More frequently than in older women, the malignancy is genetically determined [7] .
Pregnancy does not worsen patients' prognoses and breast cancer therapy in pregnancy does not differ much from that of non-pregnant patients. The basic limitation is the time of therapy initiation: optimally, it is the second gestational trimester due to foetal organogenesis that occurs during the first weeks of gestation and an absolute ban on endocrine and trastuzumab therapy throughout pregnancy [7] . Because of breast cancer patients' young age and sometimes long-lasting overall survival rates, one can expect (at least in some of them) late complications after oncological therapy. Therefore, every effort must be made to protect the circulatory system from cardiotoxic side effects. Before trastuzumab was initiated, LVEF was reassessed: it was of 55% with no abnormalities. The patient's general state was good, she did not complain of any ailments linked to the neoplastic disease.
Currently, the patient is continuing trastuzumab therapy with good tolerance.
What is worth noticing here is the fact that histopathological tests of the primary tumor did not show HER2 overexpression even though it was found in the metastases, which opened up prospects for targeted molecular therapy. Despite AF during classical doxorubicin therapy, no further cardiotoxicities occurred during either liposomal doxorubicin or docetaxel therapy.
DISCUSSION
Liposomal doxorubicin use in patients with advanced breast cancer in first-line therapy may be an effective therapeutic option, particularly in those patients who previously underwent anthracyclines therapy [8] . Owing to its liposomal form, even large doses of this type of doxorubicin (maximal cumulative dose -1260 mg/m²) significantly lower the risk of cardiotoxcity, more than its classical form, and with a fairly good tolerance [6] .
While using liposomal doxorubicin, the doses of all the previously administered anthracyclines should be added up and calculated as a dose of classical doxorubicin. After overextending the cumulative dose of 550 mg/m² of classical doxorubicin, it is necessary to assess the left ventricular function before each consecutive liposomal doxorubicin course [9] . Such an assessment is most often done via echocardiography and, in extraordinary cases, via magnetic resonance imaging (MRI), which is still not commonly available in everyday clinical practice.
CONCLUSIONS
1. In the case of relapse occurring at least 12 months after adjuvant therapy based on anthracycline, it is worth resuming chemotherapy with doxorubicin, this time in its liposomal form.
Administration of large doses of liposomal doxorubicin
involves a lesser cardiotoxicity risk than in the case of classical doxorubicin.
3. Once the cumulative dose of 550 mg/m² has been overextended, echocardiography must be done before each consecutive liposomal doxorubicin course.
